Table_1_CRISPR/Cas9 ADCY7 Knockout Stimulates the Insulin Secretion Pathway Leading to Excessive Insulin Secretion.xlsx
Despite the enormous efforts to understand Congenital hyperinsulinism (CHI), up to 50% of the patients are genetically unexplained. We aimed to functionally characterize a novel candidate gene in CHI.
PatientA 4-month-old boy presented severe hyperinsulinemic hypoglycemia. A routine CHI genetic panel was negative.
MethodsA trio-based whole-exome sequencing (WES) was performed. Gene knockout in the RIN-m cell line was established by CRISPR/Cas9. Gene expression was performed using real-time PCR.
ResultsHyperinsulinemic hypoglycemia with diffuse beta-cell involvement was demonstrated in the patient, who was diazoxide-responsive. By WES, compound heterozygous variants were identified in the adenylyl cyclase 7, ADCY7 gene p.(Asp439Glu) and p.(Gly1045Arg). ADCY7 is calcium-sensitive, expressed in beta-cells and converts ATP to cAMP. The variants located in the cytoplasmic domains C1 and C2 in a highly conserved and functional amino acid region. RIN-m(-/-Adcy7) cells showed a significant increase in insulin secretion reaching 54% at low, and 49% at high glucose concentrations, compared to wild-type. In genetic expression analysis Adcy7 loss of function led to a 34.1-fold to 362.8-fold increase in mRNA levels of the insulin regulator genes Ins1 and Ins2 (p ≤ 0.0002), as well as increased glucose uptake and sensing indicated by higher mRNA levels of Scl2a2 and Gck via upregulation of Pdx1, and Foxa2 leading to the activation of the glucose stimulated-insulin secretion (GSIS) pathway.
ConclusionThis study identified a novel candidate gene, ADCY7, to cause CHI via activation of the GSIS pathway.
History
References
- https://doi.org//10.1136/adc.2008.148171
- https://doi.org//10.1530/JME-15-0016
- https://doi.org//10.3389/fendo.2017.00156
- https://doi.org//10.1186/1750-1172-6-63
- https://doi.org//10.1007/s00259-017-3867-1
- https://doi.org//10.1053/j.sempedsurg.2010.10.009
- https://doi.org//10.2337/dc11-1296
- https://doi.org//10.1159/000485184
- https://doi.org//10.1093/hmg/5.11.1809
- https://doi.org//10.1126/science.7716548
- https://doi.org//10.1530/EJE-08-0203
- https://doi.org//10.1056/NEJM199805073381904
- https://doi.org//10.1172/JCI200111294
- https://doi.org//10.1086/520960
- https://doi.org//10.1371/journal.pone.0003850
- https://doi.org//10.1371/journal.pmed.0040118
- https://doi.org//10.1210/jc.2012-1356
- https://doi.org//10.1159/000351943
- https://doi.org//10.1056/NEJMc1403446
- https://doi.org//10.1681/ASN.2016121312
- https://doi.org//10.1159/000111789
- https://doi.org//10.1007/s00438-020-01695-5
- https://doi.org//10.1038/s41598-020-58845-3
- https://doi.org//10.1096/fasebj.7.9.8330684
- https://doi.org//10.1074/jbc.M010361200
- https://doi.org//10.1081/RRS-120014589
- https://doi.org//10.1074/jbc.M210146200
- https://doi.org//10.1146/annurev.pa.36.040196.002333
- https://doi.org//10.1124/mol.54.2.231
- https://doi.org//10.1371/journal.pone.0110226
- https://doi.org//10.2337/db14-0494
- https://doi.org//10.2337/db13-1607
- https://doi.org//10.1146/annurev.pharmtox.41.1.145
- https://doi.org//10.1074/jbc.M414381200
- https://doi.org//10.1371/journal.pone.0024058
- https://doi.org//10.1038/srep34179
- https://doi.org//10.2337/diabetes.45.11.1478
- https://doi.org//10.1016/j.bbrc.2016.12.128
- https://doi.org//10.1128/MCB.17.10.6002
- https://doi.org//10.1186/1423-0127-17-S1-S11
- https://doi.org//10.2174/1381612821666150921110716
- https://doi.org//10.1186/1423-0127-17-S1-S11
- https://doi.org//10.1074/jbc.M802603200